Bacterial Vaginosis Diagnostics Market

Bacterial Vaginosis Diagnostics Market Analysis

The Bacterial Vaginosis Diagnostics Market size is estimated at USD 1.05 billion in 2025, and is expected to reach USD 1.49 billion by 2030, at a CAGR of 7.20% during the forecast period (2025-2030).

Bacterial vaginosis (BV) is a common vaginal condition caused by an imbalance in the normal bacterial flora of the vagina. It is characterized by an overgrowth of certain bacteria, leading to symptoms such as unusual discharge, odor, itching, and irritation. Several key factors driving the growth and evolution of the bacterial vaginosis diagnostics market are the increasing prevalence of bacterial vaginosis, advancements in diagnostic technologies, and growing awareness and education.

The increasing prevalence of Bacterial vaginosis (BV's) worldwide contributes to the expanding diagnostics market. For instance, a study published in the European Journal of Obstetrics & Gynecology and Reproductive Biology in October 2023 highlighted that the maternal and fetal outcomes among pregnant women with BV have shown significant health risks linked to the infection. Preterm birth (PTB), which has a prevalence of 17.9% and low birth weight (14.2%), is among the most common adverse fetal outcomes associated with BV in 2022.

In addition, as per the same source mentioned above, maternal complications like premature rupture of membranes (PROM), with a prevalence of 13.2%, and intrauterine infections highlight the urgency for accurate diagnostics. The rising global prevalence of BV, particularly among pregnant women, drives the demand for enhanced diagnostic capabilities in the bacterial vaginosis diagnostics market.

In addition, there is growing awareness of women’s health, which will increase the adoption of bacterial vaginosis diagnostics, thus driving the overall market. For instance, the findings from the International Microbiota Observatory in February 2024 revealed that while knowledge of vaginal health is improving, awareness is on the rise and highlighted that 44% of women are aware that bacterial vaginosis is linked to an imbalance in the vaginal microbiota and among women aged 60 and over.

Therefore, this shift in awareness has led to increased utilization of bacterial vaginosis diagnostics, which drives the bacterial vaginosis diagnostics market.

These factors will contribute to the bacterial vaginosis diagnostics market’s growth. However, the high cost of advanced diagnostic tests and lack of awareness may restrain market growth.

Bacterial Vaginosis Diagnostics Market Trends

Molecular Diagnostics Detection Segment is Expected to Witness Significant Growth Over the Forecast Period

Molecular diagnostics for bacterial vaginosis (BV) refers to the use of advanced techniques to detect the presence and composition of bacterial species in vaginal samples. Molecular diagnostics utilizes techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify specific bacterial DNA or RNA sequences associated with BV.

Molecular detection methods, particularly PCR-based assays, are revolutionizing the diagnosis of bacterial vaginosis (BV), offering a more accurate and reliable alternative to traditional methods like Nugent scoring. For instance, according to a study published in the Diagnostic Microbiology and Infectious Disease in February 2024, real-time PCR assays for key bacterial species associated with BV Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus spp. demonstrated excellent diagnostic accuracy when compared to the gold standard Nugent scoring. Real-time PCR was able to correctly identify a significant number of BV-positive cases that Nugent scoring classified as intermediate. This level of accuracy and precision highlights the growing preference for molecular diagnostics in clinical settings. As a result, the demand for the molecular diagnostics segment in the bacterial vaginosis diagnostics market is anticipated to surge.

Moreover, molecular detection methods, particularly those utilizing PCR, have proven to be a more accurate solution for diagnosing BV compared to traditional diagnostic techniques. For instance, according to the touchREVIEWS in Infectious Diseases in January 2024, the BD CORTM System and BD MAXTM Vaginal Panel utilize PCR technology to detect a wide range of infectious organisms, including those responsible for bacterial vaginosis. The accuracy of molecular assays has been demonstrated in clinical studies, where PCR-based diagnostics showed superior performance in identifying causative agents, particularly in cases where multiple pathogens are involved. This advanced detection level allows clinicians to more accurately tailor treatments, improving patient outcomes and reducing the need for follow-up healthcare visits due to misdiagnosis or incomplete treatment.

Therefore, the rise of molecular detection technologies is a key driver of the bacterial vaginosis diagnostics market, as they offer superior accuracy and efficiency compared to traditional diagnostic methods.

Manufacturers are focusing on advancements in technology and seeking approvals from regulatory bodies. For instance, in March 2023, BD's recent Food Drug and Administration 510(k) clearance for the BD Vaginal Panel on the BD COR System. This PCR-based assay detects organisms responsible for bacterial vaginosis using a single swab and test. The BD COR System allows laboratories to run these high-throughput molecular diagnostics, making it an ideal solution for large-scale testing environments. Such approvals will increase the adoption of molecular diagnostics methods within the bacterial vaginosis diagnostics market and will drive the segment’s growth during the forecasted period.

Hence, there is an increasing demand for advanced technologies to detect bacterial vaginosis and increasing approvals from regulatory bodies, which are expected to drive the molecular diagnostics segment within the market.

North America is Expected to Dominate the Bacterial Vaginosis Diagnostics Market

The North American bacterial vaginosis (BV) diagnostics market is driven by increasing awareness of women's health issues and the growing demand for accurate diagnostic tools. The rising prevalence of BV, especially among women of reproductive age, is fueling the need for early detection and treatment to prevent complications such as pregnancy-related risks. Technological advancements in molecular diagnostics and supportive government initiatives are further propelling market growth.

In the United States, the rising incidence of bacterial vaginosis (BV) among women is poised to fuel substantial growth in the BV diagnostics market. For example, a September 2024 study in the Journal of Reproductive Immunology reported that there is a high burden of bacterial vaginosis in women in the United States. This significant prevalence underscores the urgent demand for enhanced diagnostic solutions to pinpoint BV and its related pathogens accurately. With an increasing number of women addressing vaginal health issues in healthcare settings, the appetite for these diagnostic tools is set to surge, propelling the BV diagnostics market in the United States.

Moreover, the raising awareness about conditions like bacterial vaginosis, the hub aims to improve health outcomes and also fosters a greater demand for accurate and effective BV diagnostics.

For instance, an article published in April 2024 highlighted that the Healthy Pregnancy Hub, a key initiative under the Pan-Canadian Women’s Health Coalition, focuses on providing reliable and culturally sensitive information about the safety of medication use during pregnancy. This is particularly relevant for BV, as untreated infections can lead to serious complications for both the mother and the fetus. By increasing awareness of BV and its implications for pregnancy, the Healthy Pregnancy Hub can drive demand for effective diagnostic tools that facilitate early detection and treatment.

Furthermore, its commitment to bilingual resources ensures that diverse populations across Canada have access to vital information about BV, enhancing understanding and promoting proactive health measures and thereby driving the market’s growth in the country.

Therefore, the increasing prevalence of bacterial vaginosis and growing awareness in the region are poised to drive the North American market for bacterial vaginosis diagnostics.

Bacterial Vaginosis Diagnostics Industry Overview

The bacterial vaginosis diagnostics market is fragmented due to numerous companies, ranging from large global firms to smaller regional players, each offering various solutions. The key strategies market participants adopt are launches, approvals, and collaboration with other organizations to expand their footprint. The major players in the market include Becton, Dickinson and Company, Hologic, Inc., Qiagen N.V., Sekisui Diagnostics, bioMérieux SA, QuidelOrtho Corporation, Binx Health, Thermo Fisher Scientific, Cepheid and PHASE Scientific., among others.

Bacterial Vaginosis Diagnostics Market Leaders

Bacterial Vaginosis Diagnostics Market News

• January 2024: Cepheid received Food Drug and Administration clearance with a Clinical Laboratory Improvement Amendments (CLIA) waiver for its Xpert Xpress MVP, a multiplex vaginal panel. This innovative test can now be performed in near-patient settings, delivering results within 60 minutes from a single specimen to detect Bacterial Vaginosis (BV). This expanded claim underscores Cepheid's commitment to enhancing access to women's and sexual health diagnostics by making PCR testing readily available at the point of care. The Xpert Xpress MVP runs on Cepheid's GeneXpert Xpress instruments and is approved for use in women aged fourteen years and older, representing a significant advancement in the timely and accurate diagnosis of common vaginal infections.
• December 2023: Heranova Lifesciences, a pioneering company focused on women's health, has officially launched with USD 13.5 million in funding. The company aims to address critical health issues by offering advanced diagnostic tests and therapeutics specifically designed for conditions including bacterial vaginosis.